3M Net Income Plunges 39% Amid Divestiture Charges, Sales Up Modestly

TL;DR

**3M's earnings are getting hammered by divestitures, but the slight sales bump isn't enough to make me bullish on this industrial giant right now.**

AI Summary

3M Company reported a significant decline in net income attributable to 3M for the three months ended September 30, 2025, falling to $834 million from $1,372 million in the prior year, a 39.2% decrease. Diluted EPS from continuing operations also dropped to $1.55 from $2.48. Net sales, however, saw a modest increase of 3.5% to $6,517 million from $6,294 million in the same period. The company recorded a pre-tax charge of $161 million related to the agreed sale of its precision grinding and finishing business, contributing to a 'Loss on business divestitures' of $161 million for the quarter. Operating income improved to $1,447 million from $1,316 million, a 9.9% increase. Cash and cash equivalents decreased by $929 million to $4,671 million from $5,600 million at the beginning of the year. The separation of its Health Care business into Solventum Corporation in April 2024 significantly impacted year-over-year comparisons, with Solventum transition agreement income reaching $30 million for the quarter. Total assets decreased to $37,611 million from $39,868 million since December 31, 2024.

Why It Matters

This filing reveals a mixed picture for 3M, with declining profitability despite a slight revenue increase. The substantial drop in net income, largely influenced by a $161 million divestiture charge and the Solventum spin-off, signals ongoing portfolio restructuring. For investors, this indicates a company in transition, potentially sacrificing short-term earnings for long-term strategic focus. Employees in divested businesses face uncertainty, while customers may see shifts in product offerings. In a competitive landscape, 3M's ability to effectively streamline its operations and reinvest in core growth areas will be crucial for market positioning against rivals like Honeywell and DuPont.

Risk Assessment

Risk Level: medium — The company reported a significant 39.2% decrease in net income attributable to 3M for the three months ended September 30, 2025, to $834 million from $1,372 million. This decline, coupled with a $161 million pre-tax charge for the sale of its precision grinding and finishing business, indicates ongoing financial volatility and the impact of strategic restructuring on profitability.

Analyst Insight

Investors should closely monitor 3M's ongoing divestiture strategy and its impact on future earnings and cash flow. While the sales increase is positive, the significant drop in net income and the $161 million divestiture charge suggest that the company is still navigating a complex transformation. Consider holding for now, awaiting clearer signs of stabilization and growth from continuing operations.

Financial Highlights

revenue

$6,517M

operating Margin

22.2%

total Assets

$37,611M

net Income

$834M

eps

$1.55

cash Position

$4,671M

revenue Growth

+3.5%

Revenue Breakdown

Key Numbers

• $834M — Net income attributable to 3M (Decreased 39.2% from $1,372 million in Q3 2024)
• $6.52B — Net sales (Increased 3.5% from $6.29 billion in Q3 2024)
• $161M — Loss on business divestitures (Pre-tax charge for precision grinding and finishing business sale in Q3 2025)
• $1.55 — Diluted EPS from continuing operations (Decreased from $2.48 in Q3 2024)
• $4.67B — Cash and cash equivalents (Decreased from $5.60 billion at December 31, 2024)
• 531,225,048 — Common shares outstanding (As of September 30, 2025, a decrease from 539,470,303 at December 31, 2024)
• $30M — Solventum transition agreement income (For the three months ended September 30, 2025)
• $37.61B — Total assets (Decreased from $39.87 billion at December 31, 2024)
• $1.45B — Operating income (Increased from $1.32 billion in Q3 2024)

Key Players & Entities

• 3M Company (company) — Registrant and parent company
• Solventum Corporation (company) — Former Health Care business spun off by 3M
• New York Stock Exchange (regulator) — Exchange where 3M common stock and notes are registered
• $834 million (dollar_amount) — Net income attributable to 3M for Q3 2025
• $1,372 million (dollar_amount) — Net income attributable to 3M for Q3 2024
• $6,517 million (dollar_amount) — Net sales for Q3 2025
• $6,294 million (dollar_amount) — Net sales for Q3 2024
• $161 million (dollar_amount) — Pre-tax charge for precision grinding and finishing business divestiture
• $1.55 (dollar_amount) — Diluted EPS from continuing operations for Q3 2025
• $2.48 (dollar_amount) — Diluted EPS from continuing operations for Q3 2024

FAQ

Risk Factors

• Ongoing Litigation and Legal Proceedings [high — legal]: 3M faces significant legal risks, particularly related to its historical manufacturing of PFAS chemicals and combat earplug products. While the company has reached settlements, the full financial impact and potential for future claims remain a concern. For example, the company recorded a $161 million pre-tax charge in Q3 2025 related to the sale of its precision grinding and finishing business, indicating ongoing portfolio adjustments potentially linked to strategic shifts or divestitures to manage liabilities.
• Supply Chain Disruptions and Raw Material Costs [medium — operational]: The company's operations are susceptible to disruptions in global supply chains and volatility in raw material costs. For the three months ended September 30, 2025, cost of sales increased to $3,792 million from $3,647 million in the prior year, a 4.0% rise, suggesting inflationary pressures or supply chain challenges impacting production costs.
• Impact of Business Divestitures and Restructuring [medium — financial]: The ongoing separation of businesses, such as the Health Care business into Solventum Corporation and the recent sale of the precision grinding and finishing business, introduces complexity and potential financial volatility. The $161 million loss on business divestitures in Q3 2025 highlights the immediate financial impact of these strategic moves.
• Environmental, Social, and Governance (ESG) Regulations [high — regulatory]: Increasingly stringent ESG regulations, particularly concerning chemical usage and environmental impact, pose a significant risk. The company's historical involvement with PFAS chemicals places it under scrutiny, requiring substantial investment in compliance and remediation efforts. The $308 million provision for income taxes in Q3 2025, while a decrease from $348 million in the prior year, reflects ongoing tax considerations that can be influenced by regulatory changes.
• Competition and Market Share Erosion [medium — market]: 3M operates in highly competitive markets across its diverse segments. Failure to innovate or adapt to changing customer needs could lead to market share erosion. For instance, while net sales increased by 3.5% to $6,517 million in Q3 2025, this modest growth may not be sufficient to outpace aggressive competitors in certain sectors.
• Debt Management and Interest Expense [medium — financial]: While not explicitly detailed in the provided summary, managing its debt obligations is crucial. The 'Other expense (income), net' line item shows a significant swing from a net income of $405 million in Q3 2024 to a net expense of $300 million in Q3 2025, which could include interest expenses or other financial costs impacting profitability.

Industry Context

3M operates in a diverse range of industries, including healthcare, consumer goods, safety and industrial, and transportation and electronics. The company faces intense competition from both large conglomerates and specialized players in each of these sectors. Key industry trends include increasing demand for sustainable products, digitalization, and evolving regulatory landscapes, particularly in areas like environmental compliance and product safety.

Regulatory Implications

3M is subject to extensive regulatory oversight globally, covering environmental protection, product safety, and financial reporting. The company's historical involvement with PFAS chemicals and litigation surrounding its combat earplugs present ongoing regulatory and legal challenges. Compliance with evolving ESG standards and potential new regulations on chemical usage will require continued vigilance and investment.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]
5. [object Object]

Key Dates

• 2024-04-01: Separation of Health Care business into Solventum Corporation — Significantly impacts year-over-year financial comparisons and company structure. Solventum transition agreement income of $30 million was recorded in Q3 2025.
• 2025-09-30: End of Third Quarter 2025 — Reporting period for the 10-Q, showing a 39.2% decrease in net income attributable to 3M and a 3.5% increase in net sales.
• 2025-09-30: Common shares outstanding as of September 30, 2025 — 531,225,048 shares outstanding, a decrease from 539,470,303 at December 31, 2024, impacting EPS calculations.
• 2025-12-31: Effective date for ASU No. 2025-05 — New accounting standard for credit losses on accounts receivable, not expected to have a material impact.
• 2026-01-01: Effective date for ASU No. 2025-05 — New accounting standard for credit losses on accounts receivable, not expected to have a material impact.
• 2028-01-01: Effective date for ASU No. 2025-06 — New accounting standard for internal-use software, currently under evaluation for impact.

Glossary

Net income attributable to 3M

The portion of the company's net income that belongs to 3M's shareholders after accounting for noncontrolling interests. (Key profitability metric, showing a significant 39.2% decrease to $834 million in Q3 2025.)

Diluted EPS from continuing operations

Earnings per share calculated by dividing net income from continuing operations by the diluted weighted-average number of common shares outstanding, reflecting the potential dilution from stock options and convertible securities. (Indicates profitability on a per-share basis, which fell to $1.55 in Q3 2025 from $2.48 in the prior year.)

Loss on business divestitures

A charge recorded when a company sells or disposes of a business unit for less than its carrying value. (3M recorded a $161 million charge in Q3 2025 related to the sale of its precision grinding and finishing business.)

Solventum Corporation

The newly separated Health Care business of 3M, which became an independent public company on April 1, 2024. (Its separation significantly impacts year-over-year financial comparisons and company structure.)

Other expense (income), net

A line item on the income statement that includes various non-operating income and expense items, such as interest expense, gains/losses on investments, and foreign currency translation adjustments. (This line item swung from a net income of $405 million in Q3 2024 to a net expense of $300 million in Q3 2025, impacting overall profitability.)

Noncontrolling interest

The portion of equity in a subsidiary that is not attributable to the parent company. It represents the ownership interest of outside shareholders in the consolidated entity. (This is subtracted from net income to arrive at net income attributable to 3M, as seen in the Consolidated Statement of Income.)

Cumulative translation adjustment

An accounting adjustment made to reflect the impact of foreign currency exchange rate fluctuations on the financial statements of foreign subsidiaries. (This item contributed a negative $71 million to other comprehensive income in Q3 2025, compared to a positive $368 million in Q3 2024.)

Cash flow hedging instruments

Financial derivatives used to hedge against the risk of cash flow variability caused by changes in interest rates or foreign currency exchange rates. (These instruments resulted in a $21 million gain in other comprehensive income in Q3 2025, down from a $74 million loss in the prior year.)

Year-Over-Year Comparison

Compared to the prior year's third quarter, 3M reported a significant 39.2% decrease in net income attributable to 3M, falling to $834 million from $1,372 million, and a corresponding drop in diluted EPS from $2.48 to $1.55. This decline was partially offset by a modest 3.5% increase in net sales to $6,517 million. The company also recorded a $161 million loss on business divestitures in the current period, which was not present in the prior year, and experienced a notable shift in 'Other expense (income), net' from a $405 million income to a $300 million expense. The separation of the Health Care business into Solventum also significantly alters year-over-year comparability.

Key Financial Figures

• $0.01 — g at September 30, 2025 Common Stock, $0.01 par value per share 531,225,048 shares

Filing Documents

• mmm-20250930.htm (10-Q) — 2931KB
• q32025exhibit311.htm (EX-31.1) — 10KB
• q32025exhibit312.htm (EX-31.2) — 9KB
• q32025exhibit321.htm (EX-32.1) — 4KB
• q32025exhibit322.htm (EX-32.2) — 4KB
• q32025exhibit95.htm (EX-95) — 38KB
• 0000066740-25-000089.txt ( ) — 15191KB
• mmm-20250930.xsd (EX-101.SCH) — 77KB
• mmm-20250930_cal.xml (EX-101.CAL) — 105KB
• mmm-20250930_def.xml (EX-101.DEF) — 411KB
• mmm-20250930_lab.xml (EX-101.LAB) — 912KB
• mmm-20250930_pre.xml (EX-101.PRE) — 675KB
• mmm-20250930_htm.xml (XML) — 3268KB

Financial Information

PART I. Financial Information 3

Financial Statements

Item 1. Financial Statements 3 Consolidated Statement of Income 3 Consolidated Statement of Comprehensive Income 4 Consolidated Balance Sheet 5 Consolidated Statement of Cash Flows 6

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 7 Note 1. Significant Accounting Policies 7 Note 2. Discontinued Operations 7 Note 3. Revenue 8 Note 4. Divestitures 9 Note 5. Goodwill and Intangible Assets 9 Note 6. Restructuring Actions 11 Note 7. Supplemental Income Statement Information 12 Note 8. Supplemental Equity and Comprehensive Income Information 13 Note 9. Income Taxes 15 Note 10. Earnings Per Share 15 Note 11. Marketable Securities 16 Note 12. Long-Term Debt and Short-Term Borrowings 16 Note 13. Pension and Postretirement Benefit Plans 17 Note 14. Supplier Finance Program Obligations 18 Note 15. Derivatives 18 Note 16. Fair Value Measurements 21 Note 17. Commitments and Contingencies 23 Note 18. Stock-Based Compensation 46 Note 19. Business Segments 46

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 49 Overview 49 Results of Operations 50 Performance by Business Segment 53 Financial Condition and Liquidity 59

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 63

Controls and Procedures

Item 4. Controls and Procedures 63

Other Information

PART II. Other Information 64

Legal Proceedings

Item 1. Legal Proceedings 64

Risk Factors

Item 1A. Risk Factors 64

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 72

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 72

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 72

Other Information

Item 5. Other Information 72

Exhibits

Item 6. Exhibits 73 2 Table of Contents 3M COMPANY FORM 10-Q For the Quarterly Period Ended September 30, 2025

Financial Information

PART I. Financial Information

Financial Statements

Item 1. Financial Statements 3M Company and Subsidiaries Consolidated Statement of Income (Unaudited) Three months ended September 30, Nine months ended September 30, (Millions, except per share amounts) 2025 2024 2025 2024 Net sales $ 6,517 $ 6,294 $ 18,815 $ 18,565 Operating expenses Cost of sales 3,792 3,647 10,916 10,703 Selling, general and administrative expenses 820 1,062 3,032 3,322 Research, development and related expenses 297 269 870 803 Loss on business divestitures 161 — 164 — Total operating expenses 5,070 4,978 14,982 14,828 Operating income 1,447 1,316 3,833 3,737 Other expense (income), net 300 ( 405 ) 378 ( 323 ) Income from continuing operations before income taxes 1,147 1,721 3,455 4,060 Provision for income taxes 308 348 818 771 Income from continuing operations of consolidated group 839 1,373 2,637 3,289 Income from unconsolidated subsidiaries, net of taxes 2 3 51 7 Net income from continuing operations including noncontrolling interest 841 1,376 2,688 3,296 Less: net income attributable to noncontrolling interest 7 4 15 15 Net income from continuing operations attributable to 3M 834 1,372 2,673 3,281 Net income from discontinued operations, net of taxes — — — 164 Net income attributable to 3M $ 834 $ 1,372 $ 2,673 $ 3,445 Earnings per share attributable to 3M common shareholders: Weighted average 3M common shares outstanding — basic 534.1 550.6 538.4 553.1 Earnings per share from continuing operations — basic $ 1.56 $ 2.49 $ 4.97 $ 5.93 Earnings per share from discontinued operations — basic — — — 0.30 Earnings per share — basic $ 1.56 $ 2.49 $ 4.97 $ 6.23 Weighted average 3M common shares outstanding — diluted 538.1 552.7 542.1 554.5 Earnings per share from continuing operations — diluted $ 1.55 $ 2.48 $ 4.93 $ 5.92 Earnings per share from discontinued operations — diluted — — — 0.29 Earnings per share — diluted $ 1.55 $ 2.48 $ 4.93 $ 6.21 The accompanying Notes to Consolidated Fina

Notes to Consolidated Financial Statements (Unaudited)

Notes to Consolidated Financial Statements (Unaudited) Note 1. Significant Accounting Policies Basis of Presentation: The interim consolidated financial statements are unaudited but, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company's consolidated financial position, results of operations and cash flows for the periods presented. These adjustments consist of normal, recurring items. The results of operations for any interim period are not necessarily indicative of results for the full year. The interim consolidated financial statements and notes are presented as permitted by the requirements for Quarterly Reports on Form 10-Q. This Quarterly Report on Form 10-Q should be read in conjunction with the Company's consolidated financial statements and notes included in its 2024 Annual Report on Form 10-K. Certain amounts in prior periods' consolidated financial statements have been reclassified to conform to current period presentation. Investments: As discussed in Note 1 to the Consolidated Financial Statements in 3M's 2024 Annual Report on Form 10-K, 3M invests in marketable and equity securities. Equity securities mainly consist of 3M's ownership interest in Solventum, which was classified as a current equity investment (part of other current assets) in the third quarter of 2025. Classification as current or non-current is based on availability for use in current operations. New Accounting Pronouncements: Refer to Note 1 to the Consolidated Financial Statements in 3M's 2024 Annual Report on Form 10-K for a discussion of applicable standards issued and not yet adopted by 3M. Relevant New Standards Issued Subsequent to Most Recent Annual Report In July 2025, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2025-05, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets The ASU provides an optional prac